The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Tocilizumab Is Effective to Treat GCA

Tocilizumab Is Effective to Treat GCA

August 28, 2017 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Giant cell arteritis (GCA) causes granulomatous inflammation, primarily in the aortic arch and extracranial portion of the carotid artery. Patients with GCA are at increased risk for adverse events, especially during the first year after diagnosis. Although the cause of GCA is unknown, researchers have shown that patients have activated dendritic cells, T cells and macrophages, which appear to play central roles in the pathogenesis of the disorder.

You Might Also Like
  • GCA Relapse Possible When Discontinuing Tocilizumab
  • FDA Considers Tocilizumab for GCA & Piclidenoson Enters Phase 3 Trial for RA, Psoriasis
  • FDA Update: Romosozumab’s Uncertain Future; Plus Tocilizumab Approved for GCA
Also By This Author
  • Ultrasound May Be Useful for Grading Rotator Cuff Tendinopathy

New results reveal that the interleukin (IL)-6 receptor alpha inhibitor tocilizumab helps sustain glucocorticoid-free remission in patients with GCA. John H. Stone, MD, MPH, director of Clinical Rheumatology at the Massachusetts General Hospital in Boston, and colleagues compared weekly or bi-weekly treatment with tocilizumab in combination with a 26-week prednisone taper with either a 26-week or 52-week prednisone tapering plus placebo. The results of the one-year trial were published July 27 in The New England Journal of Medicine.1,2.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The researchers randomly assigned 251 patients with active GCA to one of two groups that received different doses of tocilizumab administered subcutaneously in combination with a 26-week prednisone taper (n=150). Patients were also assigned to one of two groups that received placebo and prednisone with the prednisone tapered over 26 weeks (n=50) or 52 weeks (n=51).

Both regimens—weekly and bi-weekly tocilizumab—in combination with a prednisone taper over 26 weeks were superior to placebo plus a prednisone taper of 26 weeks or 52 weeks. Specifically, approximately 50% of the patents treated with tocilizumab achieved prednisone-free remission when compared with approximately 15% of those in the placebo groups.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The investigators also found that only one quarter of patients treated with tocilizumab experienced flares compared with 68% of patients in the placebo group who underwent a 26-week taper and 49% of patients in the placebo group who underwent a 52-week taper. The investigators used this data to calculate a hazard ratio for flare of 0.23 (99% confidence interval [CI], 0.11 to 0.46) in the group that received tocilizumab weekly relative to those who received placebo and had a 26-week taper and 0.28 (99% CI, 0.12 to 0.66) in the group that received tocilizumab bi-weekly relative to those who received placebo and had a 26-week taper (P<0.001 for both comparisons).

Tocilizumab treatment was also associated with a reduction in the cumulative prednisone dose over the 52-week trial period. Specifically, the cumulative median prednisone dose over the 52-week period was 1,862 mg in each tocilizumab group, 3,296 mg in the placebo group that underwent the 26-week taper (P<0.001) and 3,818 in the placebo group that underwent the 52-week taper (P<0.001). Moreover, post hoc analyses revealed that 23% of patients who received tocilizumab weekly received open-label prednisone as escape therapy compared with 33% in the group that received tocilizumab every other week, 74% in the placebo group that underwent the 26-week taper and 55% in the placebo group that underwent the 52-week taper.

Pages: 1 2 | Single Page

Filed Under: Conditions, Drug Updates, Vasculitis Tagged With: aorta, GCA, giant cell arteritis (GCA), glucocorticoid, prednisone, Remission, tocilizumab

You Might Also Like:
  • GCA Relapse Possible When Discontinuing Tocilizumab
  • FDA Considers Tocilizumab for GCA & Piclidenoson Enters Phase 3 Trial for RA, Psoriasis
  • FDA Update: Romosozumab’s Uncertain Future; Plus Tocilizumab Approved for GCA
  • Tocilizumab Designated as Breakthrough Therapy for GCA

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)